MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Neurocrine Biosciences Inc. (NASDAQ: NBIX)*
Organization & Developments: Neurocrine
Parents
Neurocrine Biosciences Inc. (NASDAQ: NBIX)*
Children
*The Company's research and development efforts are focused on neurological and endocrine diseases and disorders.
2014: Neurocrine's movement disorder drug meets main goal in mid-stage study (2014)
2017: Biotech Forum Daily Digest: Revisiting Neurocrine Biosciences
2017: Neurocrine Biosciences: Ingrezza's Strong Launch, Pipeline To Create Value - Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
2017: The Positive Investment Case For Neurocrine Biosciences - Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
2018: Neurocrine Biosciences: Continued Upside In 2018 - Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
2018: Neurocrine Suffers Setback In Tourette Study, But Still Has A Solid Pipeline_seekingalpha.com
2019: How This Biotech With A 49% Gain In 2019 Could Double Its FDA Approvals_www.investors.com
2019: How This Biotech With A 49% Gain In 2019 Could Double Its FDA Approvals_www.investors.com
2019: Neurocrine Dives Into Gene Therapy_seekingalpha.com
2019: Shares Of Neurocrine Are Likely To Print $100 Again_seekingalpha.com
2020: Biotech Stock To Watch: Why This Leader Could Be Poised For Another Run
2020: Takeda farms out 7 neuro programs to Neurocrine in deal worth up to $2B_fiercebiotech
2021: Neurocrine Biosciences: Generic Drug Stock Seen As Underpriced By Architects For Near Gains
2021: Neurocrine Terminates Parkinson's Deal with Voyager Following Clinical Hold
2022: ‘A negative trial, not a failed trial’: Neurocrine axes in-licensed tremor program on phase 2 data
2022: Neurocrine Biosciences Goes Dumpster-Diving To Accelerate Its International Business Development_seekingalpha.com
2022: Neurocrine Biosciences Hands Out Treats For This Halloween Season_ seekingalpha.com
2023: Neurocrine’s Crinecerfont Delivered, But The Street Has Been Slow To Reward It (NBIX)
2024: Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
2024: Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth
2024: Neurocrine Shares Drop 20% Despite Meeting Primary Endpoint in Mid-Stage Schizophrenia Trial_ biospace
2024: Neurocrine, a regular name on Wall Street's M&A lists, elevates BD chief to succeed founder and CEO
2024: Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)_seekingalpha.com
2024: Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data
2024: Neurocrine's bid to save schizophrenia prospect fails
2024: Neurocrine's Crenessity ends 70-year drought with FDA nod for rare genetic disease
2024: Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels
Jumps
*Key People: Neurocrine
Finance & Acquisitions: Neurocrine